BAL
LOE Approachingdimercaprol
NDAINJECTIONINJECTABLE
Approved
May 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
BAL (dimercaprol). Approved for sunburns, wind burned, chapped lips. First approved in 1946.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BAL (dimercaprol) is an injectable chelating agent approved in 1946 for treating heavy metal poisoning, particularly arsenic, mercury, and lead exposure. The product is indicated for sunburns, wind-burned skin, and chapped lips, though these indications appear misaligned with its actual clinical use as a heavy metal antidote. Dimercaprol works by binding to heavy metals and facilitating their urinary excretion.
LOE Approaching
This aging product approaching loss of exclusivity presents limited commercial growth opportunities and likely operates with a small, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.